$RARE· SEC filing ·

RARE Reports $136M Q1 Rev, $730-760M 2026 Guidance, Crysvita $93M, Dojolvi $18M, GTX-102 Phase 3 Data 2H26

Ultragenyx Pharmaceutical Inc. · PHARMACEUTICAL PREPARATIONS · Now $23.94

+4.4% in 3d after detection

Post-detection moves

1h
1d
+3.7%
3d
+4.4%
7d
+3.2%
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS